Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Coley

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 29, 2000
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcomaH M Coley, M W Verrill, S E Gregson, et al.
Biochemical Pharmacology|May 11, 1995
The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studiesH M Coley, N Brooks, D H Phillips, et al.
Journal of Medicinal Chemistry|December 24, 1993
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methylM Jarman, H M Coley, I R Judson, et al.
Nanotechnology|August 24, 2012
Design of double-walled carbon nanotubes for biomedical applicationsV Neves, E Heister, S Costa, et al.
European Journal of Nuclear Medicine|July 20, 2000
Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PETJ S Lewis, J L Dearling, J K Sosabowski, et al.
British Journal of Cancer|January 12, 2012
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancerH M Coley, N A M Safuwan, P Chivers, et al.
International Journal of Cancer|November 4, 1996
Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamolH M Coley, M Jarman, N Brooks, et al.
Cancer Genomics & Proteomics|May 20, 2009
A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancerP Sooriakumaran, P Macanas-Pirard, G Bucca, et al.
Nanotechnology|October 6, 2009
AFM imaging of functionalized carbon nanotubes on biological membranesC Lamprecht, I Liashkovich, V Neves, et al.
Anticancer Research|July 1, 1996
The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenograftsH M Coley, M Jarman, M Jones, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|April 29, 2000
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcomaH M Coley, M W Verrill, S E Gregson, et al.
Biochemical Pharmacology|May 11, 1995
The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studiesH M Coley, N Brooks, D H Phillips, et al.
Journal of Medicinal Chemistry|December 24, 1993
Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methylM Jarman, H M Coley, I R Judson, et al.
Nanotechnology|August 24, 2012
Design of double-walled carbon nanotubes for biomedical applicationsV Neves, E Heister, S Costa, et al.
European Journal of Nuclear Medicine|July 20, 2000
Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PETJ S Lewis, J L Dearling, J K Sosabowski, et al.
British Journal of Cancer|January 12, 2012
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancerH M Coley, N A M Safuwan, P Chivers, et al.
International Journal of Cancer|November 4, 1996
Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamolH M Coley, M Jarman, N Brooks, et al.
Cancer Genomics & Proteomics|May 20, 2009
A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancerP Sooriakumaran, P Macanas-Pirard, G Bucca, et al.
Nanotechnology|October 6, 2009
AFM imaging of functionalized carbon nanotubes on biological membranesC Lamprecht, I Liashkovich, V Neves, et al.
Anticancer Research|July 1, 1996
The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenograftsH M Coley, M Jarman, M Jones, et al.
Pageof 4